Anthropic Takes the Lead in Drug Discovery for Neglected Diseases
1 min read
AI for Software Engineering (Copilots, SDLC, Testing)
-/5
In short
- Let’s be clear: Anthropic is stepping up where Big Pharma hesitates.
- They’re launching a drug development program aimed at neglected diseases that the industry deems unprofitable.
- Novartis CEO Vas Narasimhan believes AI can slash development time from twelve years to seven or eight and double the success rate.
Let’s be clear: Anthropic is stepping up where Big Pharma hesitates. They’re launching a drug development program aimed at neglected diseases that the industry deems unprofitable. Why does this matter? Because it challenges the status quo. Novartis CEO Vas Narasimhan believes AI can slash development time from twelve years to seven or eight and double the success rate. This changes the game. If you ignore this, you lose time. Anthropic is not waiting for permission; they’re taking action. This is a wake-up call for the pharmaceutical giants. Who will follow suit? Those who don’t adapt will be left behind. The future of drug discovery is here, and it’s driven by innovation and urgency.
Source: